Stockreport

Agilent Companion Diagnostic Gains Expanded FDA Approval in Urothelial Carcinoma

Agilent Technologies, Inc.  (A) 
Last agilent technologies, inc. earnings: 2/18 04:05 pm Check Earnings Report
US:NYSE Investor Relations: investor.agilent.com
PDF PD-L1 IHC 22C3 pharmDx Now Approved to Identify Certain Urothelial Carcinoma Patients for Treatment With KEYTRUDA® (pembrolizumab) SANTA CL [Read more]